Newsletter | April 14, 2021

04.14.21 -- How To Commercially Scale T-Cell Allogeneic Therapies

 
How To Commercially Scale T-Cell Allogeneic Therapies
 

This presentation discusses an innovative manufacturing methodology and fill/finish approaches to accelerate T-cell therapies to the commercial readiness phase.

Radiance Label-Free Monitoring Of AAV Transfection In HEK293 Cells
 

LumaCyte’s Radiance® instrument, which uses Laser Force Cytology™ (LFC) to measure the intrinsic biophysical and biochemical properties of single cells, has the potential to improve the characterization of cell-based adeno-associated virus (AAV) transfection and production, improving the efficiency and accuracy of both processes and shortening development time.

Manufacturing Innovation Across New Modalities
 

The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next challenge for innovators to make these new modalities available at scale. This webinar reviews and presents key areas of technology innovation to reshape the scale-up of these advanced therapeutics.

Solutions